17 results about "Reduced serum uric acid" patented technology

The invention discloses a traditional Chinese medicine composition for treating hyperuricemia and application thereof, and belongs to the technical field of traditional Chinese medicines. The preparation method of the traditional Chinese medicine composition comprises the following steps: mixing ganoderma lucidum spore powder and idesia polycarpa fruit powder according to a mass part ratio of (10-90): (90-10), extracting by using a supercritical CO2 fluid extraction technology to obtain an extract phase, then carrying out decompression analysis to precipitate an extract, and drying to obtain traditional Chinese medicine composition powder. The invention provides the traditional Chinese medicine composition compounded by the ganoderma lucidum spore oil and the idesia oil, and cell experiments and animal experiments prove that the traditional Chinese medicine composition can remarkably inhibit uric acid synthesis and reabsorption, so that the level of serum uric acid is reduced, renal function impairment caused by hyperuricemia is improved, and the curative effect is improved. The compound can be used as a functional raw material for preparing a product for treating hyperuricemia or improving kidney injury caused by hyperuricemia; the raw materials are easy to obtain, the cost is low, the safety is high, and good development and application values are achieved.

This invention discloses *Pediococcus lactis* TC-4, which simultaneously degrades nucleosides, purines, and uric acid, and its applications. *Pediococcus lactis* ( Pediococcus acidilactici This invention relates to *Pediococcus lactis* TC-4, with accession number GDMCC No: 67936. *Pediococcus lactis* TC-4 of this invention can efficiently degrade three nucleosides (guanosine, adenosine, and inosine), three purines (guanine, xanthine, and hypoxanthine), and uric acid in vitro. *Pediococcus lactis* TC-4 of this invention can effectively reduce serum uric acid levels in broiler chickens, alleviating and treating hyperuricemia. Compared with traditional chemical drugs for treating hyperuricemia and / or gout, this invention has no toxic side effects on the ecological environment, no residue risk, and is green and safe. This invention has been confirmed at multiple levels, including genetic and animal studies, to have no potential harm to humans, demonstrating its advantages of safety and high efficiency.

The present application belongs to the technical field of bioactive peptides, functional food and biological medicine, and particularly relates to a marine fish-derived xanthine oxidase inhibiting heptapeptide NPLVTPP and its application in reducing uric acid. The present application discloses a marine fish-derived heptapeptide NPLVTPP with xanthine oxidase inhibiting activity, and the amino acid sequence of the heptapeptide is Asn-Pro-Leu-Val-Thr-Pro-Pro. The heptapeptide can be prepared by solid-phase chemical synthesis or marine fish protein enzymatic separation and purification, can significantly inhibit xanthine oxidase activity, reduce uric acid generation, can effectively reduce serum uric acid level in a hyperuricemia animal model, and can improve high uric acid related kidney function damage. The present application also protects the application of the heptapeptide in preparing xanthine oxidase inhibitors, uric acid reducing products, products for preventing or improving hyperuricemia and kidney damage, and a medicine, food or nutritional composition containing the heptapeptide. The polypeptide sequence of the present application is clear, the target is clear, the in vivo and in vitro efficacy is clear, the source is safe, and the polypeptide can be used in the fields of functional food and biological medicine.

The invention provides a roxburgh rose source intelligent delivery system and a preparation method and application thereof. The system is formed by self-assembling roxburgh rose endogenous components through physical field programming induction, and simultaneously meets the following requirements: (1) the molar ratio of Cu < 2 + > to Mn < 2 + > is (1: 5.5)-(1: 6.5), and the molar ratio of Cu < 2 + > to Sr < 2 + > is (1: 0.45)-(1: 0.51); (2) the Zeta potential is-5 mV to + 5 mV, and the conductivity is lt; 10 S / cm; (3) a release rate lt in simulated gastric juice; the release rate gt in simulated intestinal juice within 2 hours is 10%; 80%; and (4) in terms of solids, single administration MTD is greater than or equal to 5.0 g / kg. The system has nearly neutral Zeta potential and extremely low conductivity, keeps stable in long-term storage, can synergistically reduce serum uric acid, transaminase and blood sugar, and has a kidney protection effect while efficiently reducing uric acid. The invention further provides a green preparation method of the system and multi-field application of the system.

The invention relates to the technical field of microorganisms and biological medicines, in particular to triple probiotics as well as a preparation method and application thereof, and the triple probiotics comprise at least one probiotic of bacillus, lactobacillus acidophilus and bifidobacterium longum. The triple probiotics provided by the invention form an'oxygen consumption-enzyme production-acid production 'synergistic chain, and through synergistic degradation of uric acid, inhibition of excessive growth of conditioned pathogens and enhancement of intestinal barrier functions, the blood uric acid level of patients with asymptomatic hyperuricemia is reduced, the alpha-diversity of intestinal tracts is improved, the abundance of butyric acid producing bacteria is improved, and the content of the butyric acid producing bacteria is improved. The ratio of escherichia coli to shigella is reduced; sIBO is effectively relieved or reversed, and digestive tract symptoms such as abdominal distension and exhaust are reduced. In addition, the triple probiotics avoid liver and kidney toxicity caused by chemical drugs, and are suitable for long-term administration.

The invention provides an application of pithecellobium clypearia, and discloses an application of 7-galloyl telicolor flavane in resisting inflammation, inhibiting xanthine oxidase activity and treating hyperuricemia related diseases for the first time. Through enzyme inhibition tests, molecular docking and molecular dynamics simulation, the inhibition effect and the action mechanism of the 7-galloyl tericolor flavane on the activity of xanthine oxidase are discussed, the 7-galloyl tericolor flavane has excellent xanthine oxidase inhibition activity, and the half inhibitory concentration IC50 value of the 7-galloyl tericolor flavane is 6.75 + / -0.67 mu M. Experiments prove that the 7-galloyl telicolor flavane can remarkably reduce the serum uric acid level of a hyperuricemia mouse model, can reduce the oxidative stress level of a mouse, protects liver and kidney from being damaged during oxidative stress, and shows that the 7-galloyl telicolor flavane can be used for treating kidney injury caused by uric acid, and has a good application prospect. The compound has potential application value in the aspects of anti-gout drugs, anti-hyperuricemia drugs and the like.

The invention discloses fermentation mucus lactobacillus with a uric acid reducing function and application of the fermentation mucus lactobacillus. The fermentation mucus lactobacillus is preserved in the China General Microbiological Culture Collection Center on August 4, 2025, and the preservation number is CGMCC No.35505. The invention further discloses a preparation method of the fermentation mucus lactobacillus. The fermented lactobacillus mucus has excellent creatinine degradation capability, can reduce serum uric acid, creatinine and urea nitrogen levels of an individual with hyperuricemia, and alleviates liver or kidney injury caused by the individual with hyperuricemia; in addition, the fermented lactobacillus mucus can also improve the composition of intestinal flora and inhibit the abnormal change of the flora related to metabolic disorder, thereby restoring the stable state of the microecology of the intestinal tract. Therefore, the fermented lactobacillus mucilaginosus can be used for preparing uric acid reducing functional foods, health foods or microecological preparations.

The invention discloses an application of Dubosiella Newyorkensis in prevention and / or treatment of hyperuricemia, and belongs to the field of biological medicines. The invention relates to an application of Dubosiella Newyorkensis in prevention and / or treatment of hyperuricemia and a preparation method of the Dubosiella Newyorkensis. A hyperuricemia mouse model induced by high-purine diet is taken as an experimental subject, and the effect of the dunaliella in reducing serum uric acid of an organism is proved. Results show that the dunaliella can reduce the level of serum uric acid, promote excretion of intestinal uric acid, up-regulate the expression level of intestinal ABCG2 protein and relieve intestinal mucosa injury. The dunaliella has wide application value in preparation of products for improving hyperuricemia.

The invention provides resveratrol-EGCG (epigallocatechin gallate) composite nanoparticles for reducing serum uric acid and a preparation method of the resveratrol-EGCG composite nanoparticles, and belongs to the technical field of nutritional active ingredient delivery systems. The resveratrol-zein-EGCG-carrageenan-chitosan composite nanoparticles are prepared by taking zein, carrageenan and chitosan as carriers and combining an anti-solvent precipitation method, a layer-by-layer assembly method and an ion induction method. Compared with free resveratrol and EGCG (epigallocatechin gallate), the composite nanoparticles have the advantages that the physical and chemical stability of resveratrol and EGCG is remarkably improved, the biological activity and efficacy performance of resveratrol and EGCG are improved, a stronger serum uric acid reducing effect is realized, and the composite nanoparticles have a good application prospect in the aspect of development of uric acid reducing functional products.

The invention discloses an application of cinchona element Ia as a uric acid lowering drug, and finds that the cinchona element Ia has a remarkable inhibition effect on expression of GLUT9 protein for the first time, and reabsorption of the kidney to uric acid can be effectively reduced by inhibiting expression of the GLUT9 protein, so that excretion of the uric acid from urine is promoted, the serum uric acid level is reduced, and the toxic and side effects of the kidney are reduced. And a new effective way is provided for treatment of hyperuricemia and gout.

This invention relates to a strain of *Lactobacillus plantarum* with uric acid-lowering function (…). Lactobacillus plantarum YLW67 and its applications: This strain was isolated from red sour soup, a traditional fermented food from Guizhou, and is deposited at CGMCC, accession number No. 37373. This strain exhibits excellent tolerance to the gastrointestinal environment, with a survival rate exceeding 40% after treatment in simulated gastric fluid at pH 3.0 and simulated intestinal fluid at pH 8.0. In vitro experiments show that it can completely degrade inosine and guanosine within 9 hours. Animal experiments have confirmed that it can effectively reduce serum uric acid levels in hyperuricemia model mice. This invention also provides a probiotic composition containing this strain and its preparation method, including steps such as large-scale culture, cell collection, freeze-drying, and formulation. This strain and composition can be used to prepare uric acid-lowering functional foods, health foods, or dietary supplements, and have promising applications in improving hyperuricemia and related metabolic diseases.

The present disclosure relates to the field of medicaments, and particularly to use of Liriodendron chinense (Hemsl.) Sarg, or an extract thereof in the preparation of a medicament for reducing a serum uric acid level and preventing and treating uric acid nephropathy, and belongs to the field of medicaments. In one aspect, the present disclosure provides use of Liriodendron chinense (Hemsl.) Sarg. or an extract thereof in the preparation of a medicament for reducing a serum uric acid level. In another aspect, the present disclosure further provides use of Liriodendron chinense (Hemsl.) Sarg. or an extract thereof in the preparation of a medicament for treating and / or preventing uric acid nephropathy.

The invention belongs to the technical field of microbial preparations, and discloses a lactobacillus salivarius strain M29 capable of reducing uric acid, a synbiotic preparation containing the strain and application of the synbiotic preparation. The lactobacillus salivarius strain M29 has a preservation number of CGMCC (China General Microbiological Culture Collection Center) No.35504 in the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms. The synbiotics preparation comprises a lactobacillus salivarius strain M29, fructo-oligosaccharide and a tremella fuciformis extract. The strain has the capacity of inhibiting the activity of xanthine oxidase in vitro and degrading inosine. The synbiotics preparation can remarkably reduce the serum uric acid level of a hyperuricemia model mouse and inhibit the activity of liver xanthine oxidase, and has a certain protection effect on the kidney. The synbiotics preparation disclosed by the invention is high in safety, strong in synergism and suitable for long-term intervention of hyperuricemia.

The present invention provides a cooperative composition of pea polypeptide and plant-derived lactic acid bacteria and its application. [Solution] Experiments have confirmed that the plant-derived lactic acid bacterium AR342 provided by the present invention can effectively inhibit xanthine oxidase activity and reduce serum uric acid levels. AR342 can also improve intestinal flora disorders caused by high uric acid, promote the proliferation of beneficial flora, and reduce the abundance of harmful intestinal bacteria. At the same time, it has been discovered that the pea polypeptide prepared by the present invention can also reduce uric acid content, and a cooperative composition of pea polypeptide and plant-derived lactic acid bacterium AR342 also has the activity of inhibiting uric acid production in the body, with an effect superior to that of treatment with plant-derived lactic acid bacterium AR342 or pea polypeptide alone. Based on the above, the present invention provides a new concept for the clinical treatment of hyperuricemia.

This invention discloses the application of aspirin eugenol ester in the preparation of drugs for improving hyperuricemia. While maintaining the pharmacological activities of aspirin and eugenol, aspirin eugenol ester shields the carboxyl group of aspirin, reducing the gastrointestinal irritation and other side effects of aspirin upon ingestion. Simultaneously, it overcomes the irritating odor and instability of eugenol, enabling it to exert therapeutic effects in improving hyperuricemia. Through multiple pathways, including inhibiting uric acid production, promoting uric acid excretion, activating antioxidant pathways, and inhibiting inflammatory and apoptotic signals, it significantly reduces serum uric acid levels in hyperuricemic rats, thereby improving hyperuricemia.

The application discloses a composition for relieving hyperuricemia and a preparation method and application thereof. The method comprises the following steps: firstly, extracting active ingredients from a traditional Chinese medicine mixture composed of chrysanthemum, spirea, sophora flower, corn silk and honeysuckle; and then, using PSBMA-glycyrrhetinic acid compound and diphenylalanine dipeptide-beta-cyclodextrin compound in sequence to load and prepare the composition. The composition is loaded with active ingredients through a cage-type interpenetrating structure, has temperature / pH dual response release characteristics, can be released in the intestinal tract, can efficiently inhibit xanthine oxidase, can significantly reduce serum uric acid, urea nitrogen and creatinine levels of hyperuricemia mice, can improve kidney function and can play an anti-inflammatory role. The application can be used for preparing granules, tablets and other medicines, and has a good application prospect in relieving hyperuricemia products.

This invention discloses two strains of *Lactobacillus reuteri* that are highly efficient at degrading nucleosides and their applications. *Lactobacillus reuteri* ( Limosilactobacillus reuteri The *Lactobacillus reuteri* strains W6-12 and W6-5, with accession numbers GDMCC No. 67938 and GDMCC No. 67937, respectively, exhibit efficient in vitro degradation of adenosine, guanosine, and inosine. In vivo, they significantly reduce serum uric acid levels in HUA broiler chickens induced by high calcium and high protein intake. Their fermented milk significantly reduces serum uric acid levels in SD rats with hyperuricemia induced by potassium hypoxanthine and hypoxanthine. This invention has been confirmed at multiple levels, including genetic and animal studies, to pose no potential harm to humans, demonstrating its safety and high efficiency.